Advertisement
Screener

IN8BIO, INC. (INAB) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

IN8BIO, INC. Operating Cash Flow

IN8BIO, INC. (INAB) reported Operating Cash Flow of -$8.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06

  • IN8BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.75M.
  • IN8BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.95M.
  • IN8BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.14M.
  • IN8BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.52M.
  • IN8BIO, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$12.71M.
  • IN8BIO, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$24.15M.
  • IN8BIO, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$23.34M.
  • IN8BIO, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$24.12M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 month
2026-06-30-$3.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$8.69M
10-Q · filed 2026-08-06
-$10.83M
derived: sum of 3 quarters · filed 2026-08-06
-$14.36M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$4.95M
10-Q · filed 2026-05-07
-$7.09M
derived: sum of 2 quarters · filed 2026-05-07
-$10.61M
derived: sum of 3 quarters · filed 2026-05-07
-$14.54M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$2.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
-$5.66M
derived: sum of 2 quarters · filed 2026-03-12
-$9.59M
derived: sum of 3 quarters · filed 2026-08-06
-$12.71M
10-K · filed 2026-03-12
2025-09-30-$3.52M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$7.45M
derived: sum of 2 quarters · filed 2026-08-06
-$10.57M
10-Q · filed 2025-11-06
-$14.60M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$3.93M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$7.05M
10-Q · filed 2026-08-06
-$11.08M
derived: sum of 3 quarters · filed 2026-08-06
-$17.19M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$3.12M
10-Q · filed 2026-05-07
-$7.15M
derived: sum of 2 quarters · filed 2026-05-07
-$13.26M
derived: sum of 3 quarters · filed 2026-05-07
-$19.35M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$4.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
-$10.14M
derived: sum of 2 quarters · filed 2026-03-12
-$16.23M
derived: sum of 3 quarters · filed 2026-03-12
-$24.15M
10-K · filed 2026-03-12
2024-09-30-$6.11M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$12.20M
derived: sum of 2 quarters · filed 2025-11-06
-$20.12M
10-Q · filed 2025-11-06
-$24.97M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30-$6.09M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$14.01M
10-Q · filed 2025-08-07
-$18.86M
derived: sum of 3 quarters · filed 2025-08-07
-$24.57M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31-$7.92M
10-Q · filed 2025-05-07
-$12.77M
derived: sum of 2 quarters · filed 2025-05-07
-$18.48M
derived: sum of 3 quarters · filed 2025-05-07
-$23.82M
derived: sum of 4 quarters · filed 2025-05-07
2023-12-31-$4.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13
-$10.56M
derived: sum of 2 quarters · filed 2025-03-13
-$15.90M
derived: sum of 3 quarters · filed 2025-03-13
-$23.34M
10-K · filed 2025-03-13
2023-09-30-$5.71M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
-$11.05M
derived: sum of 2 quarters · filed 2024-11-12
-$18.49M
10-Q · filed 2024-11-12
-$26.44M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30-$5.34M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
-$12.78M
10-Q · filed 2024-08-08
-$20.73M
derived: sum of 3 quarters · filed 2024-08-08
-$26.47M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$7.44M
10-Q · filed 2024-05-09
-$15.39M
derived: sum of 2 quarters · filed 2024-05-09
-$21.13M
derived: sum of 3 quarters · filed 2024-05-09
-$27.00M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$7.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
-$13.69M
derived: sum of 2 quarters · filed 2024-03-14
-$19.56M
derived: sum of 3 quarters · filed 2024-03-14
-$24.12M
10-K · filed 2024-03-14
2022-09-30-$5.74M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
-$11.61M
derived: sum of 2 quarters · filed 2023-11-09
-$16.17M
10-Q · filed 2023-11-09
-$18.35M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30-$5.87M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
-$10.43M
10-Q · filed 2023-08-10
-$12.61M
derived: sum of 3 quarters · filed 2023-08-10
-$18.97M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31-$4.56M
10-Q · filed 2023-05-12
-$6.74M
derived: sum of 2 quarters · filed 2023-05-12
-$13.10M
derived: sum of 3 quarters · filed 2023-05-12
-$15.56M
derived: sum of 4 quarters · filed 2023-05-12
2021-12-31-$2.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30
-$8.54M
derived: sum of 2 quarters · filed 2023-03-30
-$11.00M
derived: sum of 3 quarters · filed 2023-03-30
-$13.51M
10-K · filed 2023-03-30
2021-09-30-$6.37M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
-$8.83M
derived: sum of 2 quarters · filed 2022-11-10
-$11.33M
10-Q · filed 2022-11-10
-$13.06M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30-$2.46M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12
-$4.97M
10-Q · filed 2022-08-12
-$6.69M
derived: sum of 3 quarters · filed 2022-08-12
-$8.82M
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31-$2.51M
10-Q · filed 2022-05-12
-$4.23M
derived: sum of 2 quarters · filed 2022-05-12
-$6.36M
derived: sum of 3 quarters · filed 2022-05-12
2020-12-31-$1.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17
-$3.85M
derived: sum of 2 quarters · filed 2022-03-17
-$7.13M
10-K · filed 2022-03-17
2020-09-30-$2.12M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
-$5.41M
10-Q · filed 2021-11-10
2020-06-30-$3.28M
10-Q · filed 2021-09-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)United States$0.013B-1.05
INTENSITY THERAPEUTICS, INC. (INTS)United States$0.013B-1.08
Pluri Inc. (PLUR)$0.014B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
Passage BIO, Inc. (PASG)United States$0.015B-0.43
DYADIC INTERNATIONAL INC (DYAI)United States$0.016B
BioCardia, Inc. (BCDA)United States$0.016B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B